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  ABSTRACT 
Breast cancer is the second highest leading cause of mortality among women. There 
are many factors responsible for promoting breast cancer. One of the risk factor of this 
malignancy is molecular alterations. The molecular alterations include epigenetic regulations 
such as regulation by microRNAs (miRNAs). miRNAs are a group of small non-coding 
RNAs, about 18-25 nucleotides in length. These miRNAs have the potential to regulate 
mRNA expression by suppressing the translational activity. In this study, we aim to identify 
miRNAs which might have a role in breast cancer. For this, we analyzed expression data of 
miRNAs and mRNAs in breast cancer tissues and identified the sets of miRNAs and mRNAs 
that are differentially expressed in breast cancer. Considering sets of up-regulated miRNA 
and down-regulated mRNAs, we constructed miRNA-target interaction map and screened 
few miRNA-target pairs (hsa-miR-27a-3p:ADAMTS5 & hsa-miR-17-5p: CX3CL1) that are 
hypothesised to play a role in breast cancer malignancy. To confirm the expression of these 
miRNAs and mRNAs in breast cancer, we performed qRT-PCR of each of the mRNAs and 
miRNAs in MDA-MB-231 cell line and found that miRNAs- hsa-miR-27a-3p, hsa-miR-17-
5p that target ADAMTS5 and CX3CL1 respectively are up-regulated and the corresponding 
targets are down-regulated. This inverse correlation in expression of these miRNAs and 
mRNAs supplemented with presence of target sites identified from target prediction indicate 
that these two miRNAs might be regulating the expression of these two mRNAs which in 
turn might be playing a crucial role in breast cancer. miRNA targeting can be further 
confirmed by luciferase reporter assays. We also performed methylation specific PCR (MSP) 
of ADAMTS5 to find the possibility whether its expression is modulated by methylation, 
rather than miRNAs before proceeding for reporter assays. 
 
Key words: breast cancer, microRNA, epigenetic regulation, gene expression, MSP 
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INTRODUCTION 
                Living bodies are generally made up of billions of living cells. These cells grow 
and divide into normal cells and die an orderly way. The normal cells replace the oldest and 
the apoptotic cells. When cells of the body grow in an uncontrolled way, cancer is caused. 
Cancer cells have properties of uncontrolled growth without dying and form new abnormal 
cells unlike normal cells. Cancer cells can invade the other tissues and spread to different 
locations. Cells become cancerous due to DNA damage. Normally DNA damages are 
repaired by various mechanisms involved in maintaining tissue homeostasis, however, in case 
of cancer cells, DNA damage is not repaired and the unwanted cells proliferate instead of 
being removed. Sometimes DNA damage is inherited, but mostly it is due to the change in 
normal cells and the environmental factors. So, cancer is a multifactor disease caused due to 
molecular alterations in the genome of somatic cells. 
 The process of formation of cancer called as oncogenesis or tumorogenesis is caused 
by interplay between genetic/epigenetic and environmental factors. There are specific traits 
which are called hallmarks that convert normal cells to cancerous cells. These hallmarks are-
i) ability to stimulate their own growth, ii) ability to resist inhibitory signals iii) ability to 
resist their own programmed cell death (apoptosis), iv) ability to induce formation of blood 
vessels (angiogenesis) to supply nutrients to tumors, v) ability to multiply forever, vi) ability 
to invade local tissue and spread to distant sites known as metastasis. Apart from these six 
hallmarks, few hallmarks have been added recently to the list. These are- i) abnormal 
metabolic pathways, ii) ability to evade the immune system, iii) chromosome abnormalities 
and unstable DNA, and iv) inflammation (Weinberg and Hanana 2000). 
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Figure 1. The hallmarks of Cancer 
 Most tissues of human body are not necessarily susceptible to cancer, but the breast 
tissue is unique in its composition with vulnerability and ability to change with the response 
of hormones. Breast cancer is a highly deadly disease and the second most susceptible among 
women, but not yet well understood. Globally, it is estimated that the incidence and mortality 
rate of breast cancer have increased over the past 30 years, at annual rates of 3.1% and 1.8% 
respectively (Luciani et al., 2009). Breast cancer patient have very good chances of a disease 
free survival if the cancer is diagnosed and treated in early stages. 
 A survey on breast cancer conducted in 2014 by the American Cancer Society, United 
States indicate below figures: 
· New Diagnosed case of invasive breast cancer is about 232,670. 
· Carcinoma in situ (CIS) breast cancer diagnosed cases are about 62,570. 
· Mortality of women due to breast cancer is about 40,000. 
  
 Clinical data of breast cancer patients was recorded in different parts of India, particularly in 
Chennai, Bangalore, Mumbai, Barshi, Bhopal and Delhi from the year 1982/88 and 2007/08. 
By analysis of such data recorded at different places and different time intervals, it was found 
that the percentage of breast cancer cases increases when increasing time duration (Asthana 
et al., 2014). 
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Fig 2: The percentage data of breast cancer patients reported in different cities of India in 
year 1982/82 and 2007/08. 
 
 There are several types of breast cancer depending upon the size of tumors-  
ü Ductal carcinomas in situ (DCIS) also known as intraductal carcinoma,  
ü Lobular carcinoma in situ,  
ü Invasive ductal carcinoma and  
ü Invasive lobular carcinoma.  
The changes in molecular profile and morphology of breast tissue are observed because it has 
greater susceptibility to DNA damage through tissue damage. When a cell replicates more 
rapidly, its genetic codes are more vulnerable to damage by chemicals, viruses and radiations 
that later causes cancer.  Various deregulated mechanisms in a cell can lead to cancer, such as 
genetic alternation, epigenetic mechanism and microRNA regulation etc. The germline 
mutations in genes like BRCA1(Breast cancer 1, early onset and BRCA2 (breast cancer 2, 
early onset) are reported to be associated with high risk of breast cancer in the early age. 
Besides genetic alterations, it has been reported recently that breast cancer is mainly 
regulated mainly by epigenetics mechanisms, either by DNA methylation or by the small 
non-coding RNA (ncRNA) mediated regulation. 
DNA methylation, a biochemical process that involves addition of a methyl group to 
the cytosine residue is essential for normal mammalian development and is associated with a 
number of processes like genomic imprinting, inactivation of X-chromosomes, suppression of 
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repetitive elements, carcinogenesis and transcription of genes. The transcription of genes are 
affected by DNA methylation in two ways-  
i) methylation of DNA itself may physically impede the binding of transcription 
factor to the gene,  
ii) methylated DNA bound by protein known as methyl CpG binding domain 
proteins (MBDs) which impedes transcription. 
 It is known that methylation dependent mechanisms are associated with silencing of tumor 
suppressor genes which enhance the progression, initiation and development of breast cancer. 
The tumor suppressor gene, p16 has been reported to be silenced by hyper-methylation of 
promoter and promotes breast cancer (Stefansso et al., 2011). There can be many more genes 
that can be involved in breast cancer. Moreover, these genes may be regulated by another 
epigenetic mechanism, i.e., small ncRNAs. 
 MicroRNA (miRNA) is one such group of small ncRNAs that have potential role in 
cancer biology including breast cancer. miRNAs are mainly 20-24 nucleotides long. These 
recognise their target mRNA based on the sequence complementarity mainly to 3/UTR 
regions and inhibit protein translation. miRNAs are involved in cellular differentiation and 
proliferation in addition to numerous other functions and their de-regulation leads to cancer. 
Till date, many miRNAs have been identified that are associated with the breast cancer. In 
one recent study, it was found that 7 miRNAs (miR-200c, miR-205, miR-203, miR-141, miR-
34a, miR-183, and miR-375) were down-regulated and 4 miRNAs) (miR-146a, miR-138, 
miR-125b1 and miR-100) were up-regulated in breast cancer as compared to normal cells 
(Luo et al., 2013). From another study, miR-21 was reported to be up-regulated and its target 
BCL2 which leads to breast cancer was found to be downregulated (Lindsey et al., 2012). 
The reason for high mortality rate of breast cancer is metastasis. When a solid tumor enters 
into adjacent tissues and spreads to the other parts of the body, the complete mechanism 
involved in the process is known as metastasis. Some miRNAs have been reported to be 
involved in metastatic process by targeting key genes like E-cadherin. E-cadherin plays an 
important role in cell-cell adhesion and maintaining the cell structure. It is a tumour 
suppressor gene and widely used as diagnostic biomarker in breast cancer. Loss of E-cadherin 
increases the tumour progression (Singhai et al., 2011). The mortality and invasion ability of 
breast cancer is increased by miR-9 which target E-cadherin (Ma et al., 2010). Similarly 
CD44 targeted by the miR-373/520 also helps in migration and invasion of breast cancer. 
miR-10b, miR-21, miR-29a, miR-155 also enhances the metastatic condition in breast cancer 
(Singh and Mo, 2012).  
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 In this work, we planned to identify significant epigenetic regulations of few selected 
genes that might be responsible for breast cancer oncogenesis. To fulfil our proposed aim, we 
studied miRNAs and mRNAs that are significantly de-regulated in breast cancer and 
interactions among them followed by target analysis and quantification of both selected 
mRNAs and miRNAs by qPCR to establish their correlation of regulations. We also tried 
methylation-specific PCR to know whether these selected de-regulated mRNAs are 
modulated by methylation of their promoters in breast cancer cell lines (MDA-MB-231).    
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REVIEW AND LITERATURE 
1. CANCER 
Cancer refers to the uncontrolled growth and proliferation of abnormal cells which 
invades other tissues due to the DNA damage or mutation. Blood circulatory system and 
lymph nodes helps cancer cells to spread throughout the body. The unwanted extra cells 
aggregate to form mass of cell which is known as tumour. But all tumours are not 
cancerous. Based on the nature of tumor they can be classified into two types: 
· Benign tumors 
These are not cancerous. Benign tumour cells do not spread o other parts of the body. 
They can be removed and very rare to encounter again in the body.  
· Malignant tumors 
Malignant tumors are cancerous. These cells invade nearby tissues and spread to other 
parts of the body. This spreading of cancer from one part of body to other is called 
metastasis. Malignant tumors possess the nature of being converted into different cancer 
types. There are over 100 types of cancers discovered which affect different parts of body. 
All cancers are unique by its own effects, symptoms and methods of treatment. 
                     
Cell division Cell division
BENIGN TUMORS MALIGNANT TUMORS
          
Figure 3: Benign tumors and Malignant tumors 
 
A. Classification of cancer based on tissues of origin 
Carcinoma:  It is a type of cancer which originates in all epithelial tissues and covers the 
glands, surfaces and the body structure. 80-90% of cancers are carcinomas. Some examples 
of this type of cancer are cancer of lung, prostrate, breast, colon, pancreas, gastric and brain. 
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Sarcoma: It is a type of cancer that occurs in connective tissues like tendon, cartilage, 
ligaments, fat, bones and muscles. Sarcoma is developed from transformed mesenchymal 
origin cells. e.g. osteosarcoma. 
Lymphoma: It is a cancer type that originates in the nodes or glands of the lymphatic 
systems.  
Myeloma: Myeloma grows in the plasma cells and bone marrows. 
Blastoma: Blastoma is caused by the malignancies in precursor cells and commonly seen in 
children. e.g. Chondroblastoma occurs due to the precursor of chondrocytes. 
B. Organ specific cancer: 
The cancer is classified according to their location in the body. Specific organs have 
specific type of cancer.  
Table no: 1 common organ specific cancer type and their estimated new cases and mortality 
case reported by NCI (National Cancer Institute). 
  
 
 
 
 
 
 
 
 
2. Breast cancer: 
Cancer type new cases Mortality case 
Bladder  74,690 15,580 
Breast 232,670 40,000 
Endometrial 52,630 8,590 
Colon and rectal 136,830 50,310 
Brain  23,380 14,320 
Leukaemia 52,380 24,090 
Lung 224,210 159,260 
Melanoma 76,100 9,710 
Non- Hodgkin lymphoma 70,800 18,990 
Thyroid 62,980 1,890 
Prostrate 233,000 29,480 
Pancreatic 46,420 39,590 
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Breast cancer is a malignant tumour that starts from the cells of breast. It grows 
rapidly and may invades others areas of the body. Female mortality rate is greatly influenced 
by breast cancer. 
GENERAL BREAST CANCER TYPES 
Carcinoma 
Carcinoma begins at inner layer (epithelial cell) of breast. Carcinoma exhibits 
abnormal malignant properties of tumour tissue derived from the putative epithelial cells. 
Adenocarcinoma 
Adenocarcinomas start from glandular tissue of breast that are present inside the duct 
and lobules of the breast. 
Carcinoma in situ 
The early stage of breast cancer is known as carcinoma in situ and is confined to the 
ducts. The cells do not grow deeper in these tissues and do not invade other organs in the 
body. Ductal carcinoma in situ of the breast is referred to as non-invasive or pre-invasive 
breast cancer but it sometimes develops into an invasive breast cancer if the cancer left 
untreated. Lobular carcinoma in situ is confined to the lobules of breast. It is not a true 
cancer also reffered to as the pre-cancer. 
 
Invasive carcinoma  
An invasive carcinoma develops beyond the starting point from where they have 
started growing. Invasive carcinoma is of two types, ductal invasive carcinoma and invasive 
lobular carcinoma. 
 
Different risk factors influencing Breast cancer 
Aging 
  Risk of breast cancer is increases with age. Most invasive breast cancer patients are 
found to be around the age of 55 or more. 
Overweight 
  After menopause, generally there is a lot of weight gain which increases the risk of 
the breast cancer. The more production of the estrogen level in the body after menopause 
promotes breast cancer which is due to the high level of fat deposition. Being overweight also 
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triggers amount of insulin in the blood. The higher amount of insulin also acts as a risk factor 
for many cancers including the breast cancer. 
 Chest radiation: 
Women, who are treated with radiation therapy for the treatment of other cancers like 
Hodgkin disease or non-hodgkin lymphoma in the chest area ever in their life, have risk of 
developing the breast cancer.  
Drinking alcohol: 
The alcohol consuming women have more risk towards breast cancer. It was reported 
that the women who are habituated of consuming one drink/day were less affected to those 
who used to consume 2-5 drinks/day (American Cancer Society 2012). Women who do not 
consume alcohol have less risk of breast cancer. 
Tobacco Smoking: 
Tobacco contains the chemicals that are carcinogenic in nature.  
Molecular factors for breast cancer 
Other than the above mentioned factors, some molecular alterations promote breast 
cancer. Breast cancer is caused by the mutation of genes and inherited from one generation to 
the next generation. About 5% to 10% of breast cancer is hereditary (American Society 
2012). BRCA1 and BRCA2 genes are two well known tumour suppresser genes, which 
prevent cancer. If these genes were mutated and inherited from the parents, breast cancer risk 
will be high during the lifetime (Petrucelli et al., 2010). The TP53 gene helps in making the 
p53 proteins and stops the abnormal cell growth. Li-Fraumeni syndrome is caused due to the 
inherited mutations in this gene. People suffering from this syndrome were at high risk of 
developing breast cancer (Walsh et al., 2006). CHEK2 gene which have role in DNA damage 
and helps in the regulation of cell growth, also promotes breast cancer (Nevanlinna 2006 and 
Bartek 2006). The mutated PTEN causes Cowden syndrome. People suffering from Cowden 
syndrome have high risk of benign as well as malignant tumours (Liaw et al., 1997). 
 
Signalling pathways involved in breast cancer    
In breast cancer, many signalling pathways are interconnected. Signalling pathways 
are involved in cell cycle, cell division, migration, proliferation and all other biological 
processes. The tyrosine kinase signalling pathways help the normal cells to survive and 
proliferate (Lemmon and Schlessinger, 2010). The deregulation of the receptor tyrosine 
kinase by oncomirs causes cancer. HER2, a subtype of breast cancer is 30% more prevalent 
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and is caused mainly due to deregulation of EGFR signalling (Giancotti, 2003). Mutation in 
the subunit PIK3CA of PI(3)K in breast cancer alters the gene expression of PTEN and 
promotes various cancers including breast cancer (Brendan et al., 2006). In subsets of breast 
cancer, the PTK2, FAK is amplified by the deregulation of the integrin molecules. Integrin 
molecules are part of the supportive matrix which activate the receptor kinase activity 
(Giancotti, 2003) and reinforce the mitogenic signalling by regulating the Ras, PI(3)K and 
Rho family GTPase in the process of the cell adhesion and migration (Giancotti and Tarone, 
2003). E-cadherin encoded by the CDH1 is inactivated in breast cancer. In breast cancer, the 
PI(3)K is mutated and activates the mTORC2, simultaneously activating the Akt, SGK kinase 
which inturn inactivates the TOR-PI(3)K which is involved in breast cancer. Notch receptors 
are more in the breast cancer.  
 
FAK                         ER                                 HER2                            MET 
Ligand                    Ligand                             Ligand                           Ligand  
FAK                         ER                                 HER2                             MET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: signalling pathways in breast cancer 
 
Breast cancer is mainly progresses through tumour initiation and metastasis. In all the 
cases gene expression changes which alteres the normal cells. The change in gene expression 
is either due to activation of oncogenes or the repression of tumour suppressor genes. 
        Cell proliferation                 promoter 
CrK/CAS   RAS 
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MEK 
MEPK/ERK1/2 
    PI3K 
      AKT 
    mTOR 
Src 
 p
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Epigenetic mechanisms changes basic gene expressions without changing the composition of 
the sequences. Such mechanisms are active in breast cancer which causes a change in gene 
expression due to the methylation of the CpG islands in promoters of various genes and 
silencing the tumour suppressor genes by changing the chromatin structure. DNA 
methylation, post transcriptional histone modification and miRNA effect were vital 
component of epigenetic modification involved in silencing gene expression.   
 
 
Figure 5: interaction of epigenetic modification 
 
DNA METHYLATION: 
DNA methylation is the process where the additional methyl groups are attached in 
the DNA. It mainly occurs at CpG dinuclueotides (cytosine located 5’guanine). They are 
present at promoter region of more than the 70% of all genes and form clusters known as 
CpG islands (Balch et al., 2004).  Chromatin structure remodelling and the inactivation of 
transcription are due to the methylation in promoter sequence. The unmethylated CpG Island 
is open when the promoter region is surrounded by chromatin and activates the 
transcriptional factors and also the co-activators. The methyalated CpG Island have inactive 
promoter when the chromatin configuration is closed and this deactivates the transcription 
factors and co- activators. DNMTs (DNA methyl transferases) act like a catalyser in the DNA 
methylation process.  
DNA methylations at the promoter site are regulated by two mechanism which helps 
inhibition of gene expression: 
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 (i) Transcription factors recognise the methyl cytosine residues which blocks their 
binding site and inhibits the transcriptional activity (Comb and Goodman, 1990, Inamdar et 
al.,1991). 
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Figure 6: De-methylation and Methylation 
 
ii) The second mechanism helps in recruitment of the MBD proteins (methyl DNA binding 
domains) to the methylated cytosine in the promoter site (Zhang et al., 2000). HDACs 
(histone deacetylases) are present in the histone modifying complexes and are recruited by 
the MBDs proteins like NurD complex, histone methyl transferase (HMTases) at the 
promoter which inactivates the chromatin configuration (Zhang et al., 2000).  
DNA methylation role in Breast Cancer:  
DNA methylation affects various aspects of cancer system by inhibiting the 
transcriptional activity. Hypermethylation as well as Hypomethylation processes are involved 
in triggering cancer. Not only are the promoters with high CGs have methylation sites but 
also promoters with low CGs site know as “shores” are methylated differentially in several 
cancers. BRCA1, a tumour suppressor gene when mutated causes breast cancer. In invasive 
breast cancer the promoter methylation is more in comparison to the in situ carcinoma (Xu et 
al., 1999). Mortality rate is also high in case of methylated BRCA1. It has been reported that 
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there is an increase in mortality rate by 45% in methylated BRCA1 breast cancer when 
compared with that of unmethylated BRCA1 (Xu et al., 1999).  Tumour suppressor gene p16 
is methylated and found as early biomarker in breast cancer (Berman et al., 2005). 
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MicroRNA 
In all living system different biological events are mediated by biological machinery. 
Transfer of information via DNA to gene and generating the signal by protein synthesis are 
being regulated by RNAs which are also known as messenger. The non-coding or non 
translating RNAs are gaining important due to their diverse effects in biological process. One 
of such small non coding RNA is microRNA (miRNA), which have emerging role in breast 
cancer. miRNAs are endogenous and double stranded small RNAs. These are 18-25 
nucleotides long and found that they down-regulated genes by suppress the activity of 
mRNA. It found that 30% of mRNAs are regulated by the miRNA and are involved in cell 
proliferation, haematopoiesis, apoptosis, virus offense and stress response in different 
organisms, including human (Fontana et al., 2007). A single miRNA can regulate multiple 
genes and also can several miRNAs can have single target gene.  
miRNA BIOGENESIS 
miRNA regulate the gene expression by post-transcriptional mechanism and 
degradation of mRNA. RNA polymerases actively participate in biogenesis process where 
pri-miRNA transcripts are generated by the RNA polymerase II (Bartel 2009). A DGCR8 
(DiGeorge syndrome critical region 8) and Drosha protein trims the pri-miRNA (primary 
miRNA) to transcript pre-miRNA hairpin which is then exported from nucleus to cytoplasm 
by the exportin 5 (XPO5). A complex formed by the DICER and TRBP (trans-activator RNA 
(tar)-binding protein) proteins generates single stranded mature miRNA in the cytoplasm and 
incorporates it into a RNA induced silencing complex (RISC) by associating with AGO2 and 
GW182 (Hevens et al., 2012). This RISC complex delivers the miRNAs to the 
complementary site of mRNA. miRNAs are involved in gene silencing machinery. miRNAs 
binds at 3’-untranslated region (3’-UTR) of target mRNAs mainly by  complementary base 
pairing at positions 2~8 nucleotide known as “seed region” of the miRNA. The efficiency of 
target suppression by miRNA depends upon the affinity at binding sites. 
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Figure 7: Biogenesis of miRNA 
miRNA role in therapeutics 
Some miRNAs are resistant to chemotherapy and deregulation of miRNAs play role 
in therapeutic interventions. The BRCP/ABCG2 breast cancer resistance proteins are 
negatively regulated by the miR-328 and act as chemotherapeutic agent (Pan et al., 2009). 
MDR1 is upregulated by the miR-21 and interact with its target PDCD4 (Bourguignon et al., 
2009). Other miRNA that target MDR1 are miR-451(Kong et al., 2010), miR-7, miR-345. 
miR-34 targets the BCL2 and associated with the docetaxel treatment. miR-34 is highly 
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expressed and provides resistance for the radiotherapy in breast cancer (Kato et al., 2009). 
miR-221/222 is highly resistant to the anti-endocrine therapy which are prescribed for the 
ER-positive breast cancer (Miller et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bold: indicates the expression of miRNA resistance to the therapy 
Normal font:  indicates the expression of the miRNA sensitive to the therapy 
Red: indicates the miRNA alter resistance one and more therapy 
miRNA role in Breast Cancer: 
In different disease condition the genes are silenced by miRNA. miRNAs are either 
deregulated or over expressed with respect to their target genes. Breast cancer is caused by 
many miRNAs which repress various risk factor genes. Different miRNAs either behave as 
oncogenes or repress the tumor suppressor gene and promote cancer. In triple negative breast 
cancer miR-21, miR-210 and miR-221 are significantly over expressed whereas miR-10b, 
miR-145, miR-205 and miR-122a are under expressed in this cancer subtype. Some miRNA 
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like miR-21, miR-210, miR-221 are correlated with overall survival and play a significant 
role in primary triple negative breast cancer (Radojicic et al., 2011). In the ductal carcinoma 
in situ let-7d, miR-210 and miR-221 were down-regulated but were up-regulated in the 
invasive transition system (Volinia et al., 2006). miR-155 is highly expressed in many cancer 
type including the breast, lung, colon and hematopoietic cancer (Faraoni et al., 2009). In pre-
leukaemia expansion the pre-B-cell are converted into full-blown B cell tumours which is due 
to the over expression of miR-155 in early B-cells.  
Table 2: Role of miRNAs in breast cancer 
MiR Target genes Role in breast cancer 
Oncogenes   
miR-21 PDCD4, PTEN, TPM1, 
Maspin, 
BCL2, TIMP3, ANP32A, 
SMARCA4, MARCKS 
Apoptosis, cell proliferation, invasion and metastasis, 
highly expressed  
miR-10b HOXD10, T1 Metastasis, up regulated in metastasis breast cancer 
miR-155 RHOA, FOXO3a, SOCS1, 
SMAD5, SHIP1 
Over expressed, involved in epithelial mesenchymal 
transition, in hormone receptor negative tumour highly 
expressed 
miR-27a FOXO1, ZBTB10, Myt1, 
SPRY2, 
Regulated estrogen signaling, cell cycle 
Tumour 
suppressor 
  
miR-31 FZD3, ITGA5, M-RIP, 
MMP16, RDX, RHOA, 
SATB2 
Down regulates the metastasis related genes 
miR-200c BMI1, ZEB1, ZEB2, 
TUBB3, FAP1 
Prevents epithelial mesenchymal transition, down 
regulated in BC stem cell, tumour suppressing properties, 
regulates apoptosis,  
miR-18a ERalpha Higher expression in ER-negative tumours, regulates 
estrogen signalling 
miR-205 HER3, ZEB1, ZEB2, 
VEGF-A 
Down regulated, inhibits epithelial mesenchymal transition 
miR-17-5p AIB1, CCND1, E2F, 
HBP1 
Regulates cell proliferation, invasion and migration 
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miR-17-5p and breast cancer: 
miR-17-5p is located in the chromosome 13q31. The heterozygosity results in loss of 
corresponding genome region in breast cancer (Eiriksdottir et al., 1998). miR-17-5p directly 
targets the oncogene AIB1(Hossain et al.,2006), which encodes steroid receptor coactivators 
that enhance the transcriptional mechanism of ERα, E2F1. AIB1 expression is downregulated 
by miR-17-5p, which inhibits the function of ERα, E2F1 which suppresses the estrogen 
stimulated proliferation of the estrogen/ER-dependent and the estrogen/ER-independent 
cancers (Hossain et al., 2006).  
miR-27a and breast cancer 
miR-27a acts as an oncomir in breast cancer. In SKBR3 cell line, treated with pro-
apoptotic dose of LAQ824 (a histone deacetylase), miR-27a is found to be down-regulated 
(Scott et al., 2006). miR-27a also potentially target the transcriptional cofactor 
ZBTB10/RINZF, which represses SP1, a transcriptional factor functioning in the cell cycle 
transition.  
ADAM family role in breast cancer  
In cancer the proteolytic enzymes have a crucial role. ADAMs (a disintegrin and 
metalloproteinase) and ADAMTs (a disintegrin and metalloproteinase with thrombospondin 
motifs) are the matrix metallo-proteinases which help in cancer development and 
proliferation. Zinc dependent metalloproteinases also known as metzencin (Wolfsberg et al., 
1995). The domains present in the ADAMs are independent but the complementary function.  
 
Figure 8: MMP, ADAM, ADAMTS domain structure (adopted from Paulissen et al., 2009) 
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The human genome encodes 19 ADAMTSs genes (Porter et al., 2005). In the C-
terminal part additional thrombospondin type 1 motifs are present (TSP-I) and cytoplasmic 
domain and EGF like trans-membrane parts are missing. ADAMs are soluble proteins but 
some bind to the extracellular matrix by the thrombospondin motif or the spacer region 
(Porter et al., 2005). ADAM 17 is inhibited by TIMP-3(tissue inhibitor metalloproteinase). 
TIMP-1 and TIMP-3 both inhibit the ADAM 10 but TIMP-2 and TIMP-4 not have function 
on ADAM 10. TIMP does not have any effect on activities of ADAM-8, 9. 
In breast cancer, the ADAM -9, 15, 17 are highly expressed. Involved in proliferation 
and apoptosis, ADAM 12 is an apoptosis modulating gene and it up-regulated in breast 
cancer but down-regulated in the non-malignant breast cancer. The over-expression of 
ADAM 17 causes invasion and proliferation (Kumar et al., 2012). Activation of ADAM 17 is 
correlated with the urokinase plasmogen activators. In breast carcinoma cell, ADAM 28 is 
over expressed and it helps regulation of the cell proliferation through IGFBP-3 cleavage. 
ADAM 9 and ADAM 15 are also detected in breast cancer. 
ADAMTS5  
ADAMTS5 also named as ADAMTS11 is located in chromosome 21q21.3. It secretes 
matrix metalloproteinase which is 100kDa. It has two TSR where one is the central TSR and 
the other is C-terminal TSR. N terminal signal peptides help in the secretion of ADAMTS5 
(Abbaszade et al., 1999). At the C-terminal region the ADAMTS5 undergoes autocatalytic 
cleavage and forms two shorter N-terminal isoform fragments of 45 and 60kDa. the ancillary 
multi domain proteinase help in localisation and attaining substrate specificity. The 
aggrecanase activity is reduced with the loss of the c-terminal aggrecanase. The ADAMTS5 
down regulated in the malignant breast cancer as compared with to non-neoplastic mammary 
tissues (Porter et al., 2004). 
CX3CL1  
CX3CL1 is known as the fractalkine or neurotactin. Chemokines secreted by the 
extracellular spacer chemikines (C-X3-C) ligand 1 behave as an anchored precursor. 
CX3CR1 is receptor for the CX3CL1 and function as adhesion molecules (González-Martin 
et al., 2012). Chemokines act as pro and anti tumour in various cancers. It regulates the 
survival and proliferation of malignant cells as well as it has role in angiogenesis. 
CX3CL1/CX3CR1 enhances the tumour progression by transducing the proliferation, pro-
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survival signalling. CX3CL1/CX3CR1 also act as anti-tumour by enhancing the natural killer 
cells, CD8 T lymphocytes and tumour specific immune response. By targeting the epidermal 
growth factor receptor (EGFR) family the CX3CL1 promotes breast cancer (Tardáguila et al., 
2013). CX3CL1 is down regulated in the breast cancer cell line as compared to the healthy 
tissues (Tardáguila and Mañes, 2013) 
 
 
Figure 9: CX3CL1 regulation in breast cancer (adopted from Tardáguila and Mañes, 
2013) 
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OBJECTIVE 1  
The Global expression Analysis of mRNAs in the breast cancer. 
 
 
OBJECTIVE 2 
Identification of differentially expressed microRNAs in the breast cancer. 
 
 
OBJECTIVE 3 
Identification of miRNA-mRNA interaction network and screening of important 
miRNA-mRNA duplexes operating in breast cancer by using different tools. 
 
 
OBJECTIVE 4 
Quantification and Validation of selected sets of miRNAs and mRNAs by 
different experimental validation in breast cancer cell lines (MDA-MB-231) and 
HaCaT cell lines.  
 
OBJECTIVE 5 
Investigating the mode of regulation of selected set of down-regulated mRNAs 
by Methylation-specific PCR (MSP). 
 
  
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
GENE EXPRESSION 
For the analysis of mRNA and miRNA gene expression of normal as well as disease state the 
gene expression data is convenient. Gene expression analysis is further useful in therapeutic 
process and comparison study of the various expression patterns. The gene expression 
microarray data of normal vs disease sample sets are retrieved from the GEO (Gene 
Expression Omnibus) database, available at NCBI (http://www.ncbi.nlm.nih.gov/geo/). GEO 
data base is an international public repository, which stores microarray, next generation 
sequencing, and functional genomics data submitted by different research communities which 
can be retrieved easily by public users. The GEO data bases has mainly 3 goals 
i) provides durable, versatile database which storage high-thoughtful functional 
genomics data  
ii) provides simple submission procedure and format to the research community also 
supports the annotated data  
iii)  user friendly mechanism that allows public query 
For our present study expression profiles of mRNA and miRNA were taken from the GEO 
data base.  
In microarray experiments platform describes the list of features on the array (e.g cDNA, 
oligonucleotides,etc).  
Microarray analysis of gene expression data 
The microarray data were retrieves from GEO database. The data was retrieved for normal 
(control) tissues and the breast cancer (test). 
The GEO datasets Choosen 
mRNA GSE10797 
miRNA GSE38867 
 
The PLATFORM used in the GEO datasets taken: 
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mRNA GPL571: [HG-U133A_2] Affymetrix Human Genome U133A 2.0              
Array 
miRNA GPL15019:Agilent-031181 
Unrestricted_Human_miRNA_V16.0_Microarray  
 
mRNA control samples:  
GSM272727, GSM272728, GSM272729, GSM272730, GSM272731, GSM272732, 
GSM272733, GSM272734, GSM272735 
mRNA test samples: 
GSM272671, GSM272672, GSM272673, GSM272674, GSM272675, GSM272676, 
GSM272677, GSM272678,  GSM272679,  GSM272680, GSM272681, GSM272682, 
GSM272683,  GSM272684,  GSM272685,  GSM272686,  GSM272687,  GSM272688,  
GSM272689,  GSM272690,  GSM272691,  GSM272692,  GSM272693,  GSM272694, 
GSM272695, GSM272696,  GSM272697,  GSM272698,  GSM272699,  GSM272700, 
GSM272702,  GSM272703, GSM272704, GSM272705, GSM272706, GSM272707, 
GSM272708, GSM272709, GSM272710, GSM272711, GSM272712, GSM272713, 
GSM272714, GSM272715, GSM272716, GSM272717, GSM272718, GSM272719, 
GSM272720,   GSM272721,  GSM272722,  GSM272723, GSM272724,  GSM272725. 
miRNA control sample: 
GSM951048, GSM951056, GSM951060, GSM951064, GSM951068 
miRNA test sample: 
GSM951054, GSM951062, GSM951066 
The data sets were downloaded in .CEL format, unzipped and named as per convenience to 
differentiate the samples. 
 
Microarray Expression Analysis: 
The microarray data files were analysed using GeneSpring GX software. GeneSpring GX 
software provides powerful and accessible statistical tools for high speed visualization and 
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analysis of transcriptomics, genomics, proteomics and metabolomics data within a biological 
context. It includes all major microarray platform including Agilent, Affymetrix and 
Illumina. It helps to analyse all types of expressions like miRNA analysis, gene targets 
identification, correlative analysis on mRNA expression, miRNA expression, real time PCR 
data analysis etc.  
                       For the analysis the breast cancer GEO data sets it crossed multistep process. 
First a project was created. This consists of the one or more related experiments. Experiment 
comprises samples, interpretations and analyses. Samples are mainly the data sets, 
interpretation was done with grouping of samples based on experimental parameters and 
analysis is statistic steps associates results, typically entity lists. 
For mRNA expression analysis: 
1. An option of Create new experiment is chosen that allows creating a new experiment. 
The Experiment type is specified as Affymetrix Gene Chip-HGU113A. Once the 
experiment type is selected, the workflow type needs to be selected as Guided 
Workflow. 
 
2. An experiment is created using choose sample option. Experimental setup is done by 
adding average parameter which helps grouping experiment as test and control and 
replicate structure of the experiment.  
 
3. Quality control of samples is done by Filter Probe sets by Errors. This operation is 
performed on the raw signal values. The cut off for filtering was set at 20 percentile of 
all the intensity values and it generates a profile plot of filtered entities. The active 
interpretation was done by generated the plot using the normalized (not raw) signal 
values and grouped samples. 
 
4. Depending upon the experimental grouping, the Significance Analysis was done by 
performing T-test unpaired analysis as there are 2 groups, i.e. the Control and the 
Test, with Replicates. 
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5. Statistical analysis is done by T-test unpaired as a test choice. The test has been used 
for computing p-values, type of correction used and P-value computation type by 
Asymptotic method. It assumes expression values for a gene within each population 
which is normally distributed and variances are equal between populations.  
 
6. The p-value cut-off is taken ≤ 0.05. Multiple testing corrections were done by using 
Benjamini-Hochberg FDR algorithm. This algorithm is used to reduce the number of 
false positives or the false discovery rate. This Correction is the least stringent and 
tolerates more false positives. There are chances of less false negative genes. If the p-
value is ≤ 0.05, it is significant. 
 
7. Fold change analysis is used to identify genes with expression ratios or differences 
between a test and a control that are outside of a given cut off or threshold. Fold 
change gives the absolute ratio of normalized intensities between the average 
intensities of the samples grouped. The entities satisfying the significance analysis are 
passed on for the fold change analysis. The fold change cut-off is taken to be  ≥2.0. 
 
8. The analyzed data is exported by choosing export entity list with normalized signal 
values consisting of Normalization values, Gene symbol, Entrez gene IDs etc. with 
interpretation of all samples. The entity list was then saved as .txt file. 
 
9. The software used for clustering and generation of Heat map is CLUSTER 3.0. It is a 
program that provides a computational and graphical environment for analyzing data 
from DNA microarray experiments by organizing and analyzing the data in a number 
of different ways. The Cluster program provides several clustering algorithms. 
 
10. Hierarchical clustering methods organize genes in a tree structure, based on their 
similarity and assemble a set of items (genes or arrays) into a tree. Items are joined by 
very short branches if they are very similar to each other and longer branches if their 
similarity decreases. 
 
11. The software used for visualization of Heat map is Java TreeView which allows the 
organized data to be visualized and browsed by a .cdt file generated through 
CLUSTER 3.0 and is exported as image. 
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miRNA expression analysis: 
1. An option of Create new experiment is selected that allows creating a new 
experiment. The Experiment type was specified as Agilent_031181. Once the 
experiment type is selected, the workflow type was selected as Guided workflow. 
 
2. An experiment is created using choose sample option. Experimental setup was done 
by adding average parameter which helps grouping experiment as test and control and 
replicate structure of the experiment.  
 
3. Quality control of samples is done by Filter Probe sets by Errors. This operation is 
performed on the raw signal values. The cut off for filtering is set at 20 percentile of 
all the intensity values and generates a profile plot of filtered entities. The active 
interpretation was done by generated the plot using the normalized (not raw) signal 
values and grouped samples. 
 
4. Depending upon the experimental grouping, the Significance Analysis is done by 
performing T-test unpaired analysis as there are 2 groups, i.e. the Control and the 
Test, with replicates. 
 
5. Statistical analysis is done by T-test unpaired as a test choice. The test has been used 
for computing p-values, type of correction used and P-value computation type by 
Asymptotic method. It assumes expression values for a gene within each population 
which is normally distributed and variances are equal between populations. The p-
value cut-off taken was ≤ 0.05. 
 
6. Multiple testing correction is done by using Benjamini-Hochberg FDR algorithm. 
This algorithm is used to reduce the number of false positives or the false discovery 
rate. This correction is the least stringent and tolerates more false positives. There are 
chances of less false negative genes. If the p-value is ≤ 0.05, it is significant. 
 
7. Fold change analysis is used to identify genes with expression ratios or differences 
between a treatment and a control that are outside of a given cutoff or threshold. Fold 
change gives the absolute ratio of normalized intensities between the average 
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intensities of the samples grouped. The entities satisfying the significance analysis are 
passed on for the fold change analysis. The fold change cut-off is taken to be  ≥2.0. 
 
8. The analyzed data is exported by choosing export entity list with normalized signal 
values consisting of Normalization values, Gene symbol, etc. with interpretation of all 
samples. The entity list was then saved as .txt file. 
 
GENESPRING STEPs: 
 
 
 
 
 
 
 
 
 
                          
Figure 10: The multistep process of Genespring GX software 
Analysis of differentially expressed gene list 
                    The common set of genes were taken and analyzed by using GO database (Gene 
Ontology database), various technologies like Genomatrix and web based tools like Web 
based gene set analysis tool kit and their involvement in various pathways was studied. From 
the common set of genes, two genes were choosen based upon their regulation and 
association with cancer for further validation done by qRT-PCR. A set of genes involved in 
breast cancer with its regulation and fold change value was created through export list in an 
excel file. Similarly, a file was created by selecting the list of miRNAs involved in breast 
cancer with its regulation and fold change value with cut off ≥2.0. 
     The highly up-regulated miRNA and down regulated mRNAs were taken for the further 
analysis. 
 
Name the experiment. 
Experiment type: expression 
affymetrix 
Analysis type: expression 
Work flow type: biological 
significance 
Experiment note: 
 
Files uploaded Grouping 
experiment 
Create new 
project. 
Tittle/name 
Create 
interpretation Quality control Analysis OUT PUT 
28 | P a g e  
 
TARGET INTERACTION ANALYSIS THROUGH MAGIA2 
SOFTWARE: 
               Magia2 software is a web based tool which has low sensitivity of target prediction 
algorithms created by exploiting the integration of target predictions with miRNA and mRNA 
gene expression profiles for in silico target prediction where regulatory elements and their 
integrators generate a highly interconnected network of mRNA, miRNA and Transcription 
Factor (TF).   The integrated analysis of in silico target prediction, miRNA and mRNA data 
for the reconstruction of post-transcriptional regulatory networks is performed by using 
Magia2. A file containing the intensity values representing the expression of mRNAs and 
miRNAs were uploaded. The analysis was done using Pearson correlation method that aims 
to display the target interaction map for matched miRNAs and mRNA expression data. An 
interaction map was generated which showed the interconnected network of mRNAs, 
miRNAs and Transcription Factors. The miRNA-target interactions which have been 
experimentally validated (as are reported in miRecords, TarBase) are specifically marked 
within the output file. From the interaction map, two mRNAs and two miRNAs were selected 
based upon their regulation and association with breast cancer for further validation. 
 
Interaction study by NCI pathway analysis tool 
The National Cancer Institute (NCI) in collaboration with Nature Publishing Group 
has established the Pathway Interaction Database (PID) in order to provide a highly 
structured, curated collection of information about known biomolecular interactions and key 
cellular processes assembled into signaling pathways. The database focuses on the 
bimolecular interactions that are known or believed to take place in human cells. It can be 
browsed as an online encyclopedia, used to run computational analyses, or employed in ways 
that combine these two approaches. In addition to PID's predefined pathways, search results 
are displayed as dynamically constructed interaction networks. 
We used the batch query option from NCI database for functional enrichment of 
downregulated mRNAs in order to choose genes involved in crucial cellular processes. 
 
 
 
 
29 | P a g e  
 
EXPERIMENTAL VALIDATIONS 
CELL CULTURE 
              Different Cell lines were cultured for experimental validations. Human breast cancer 
cell lines, MDA-MB 231 and normal keratinocyte cell line HaCaT were procured from the 
National centre of cell science (NCCS), Pune, India. The media used for both the control and 
breast cancer cell lines is DMEM with 10% FBS and 1% antibiotics solution. Cell lines were 
cultured in culture flask in a CO2 incubator which maintained 5% CO2 level. 
CELL REVIVE 
1. Water bath was heated up to 370C. A vial of frozen cells was removed from liquid 
nitrogen and placed in the water bath until thawed. 
2. The outside of the vial was washed with 70% ethanol. 
3. The thawed cells were slowly pipeted out into sterile centrifuge tube which contained 
pre-warmed growth medium and centrifuged at 200Xg for 2min. 
4. The supernatant containing media with DMSO was decanted of aseptically and the 
cell pellet was resuspended in fresh media.  
5. The resupended cells were then cultured in 20% FBS containing media at 370C and 
5% CO2. 
TRYPSINIZING CELLS: 
1. Trypsinizing is a technique that helps to detach adherent cells from the surface of a 
cell culture vessel. This procedure is performed whenever the cells are harvested. 
2. The used media was aspirated and discarded. 
3. The cells were washed with PBS (phosphate buffer saline). 
4. 1-2ml of trypsine was added to the surface of the culture flask. 
5. The flask is then placed in the CO2 incubator at 370c for 1-2 min. 
6. The flask is then removed from incubator and lightly tapped to assist detachment of 
cells. 
7. Detached cells were resuspended in serum containing growth medium (the serum 
inactivates trypsin activity). 
8. Then the cells were pippeted up and down gently for mixing properly.  
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9. The cells were the transferred to RNAase free glass or polypropylene centrifuge tube 
and centrifuge at 200Xg for 5min. The supernant was aspirated completely and taken 
for RNA isolation. 
RNA ISOLATION 
RNA isolation was done with the RNAeasy kit of QIAGEN. 
1. Cells were centrifuged at 1000rpm for 5min. 
2. The pallet was retained and the supernatant was discarded. 
3. The cells were disrupted by adding 350µl of RLT buffer and the pallet was 
dissolved with 1 volume of (350 µl) ethanol was mixed properly by pipetting 
(do not centrifuge). 
4. Then the mixture was transferred to a RNasy mini spin column placed in a 2ml 
collection tube. The lid was closed and centrifuged for 15s at 13000rpm.Then 
the flow trough was discarded. 
5. RW1 (700 µl) buffer was added to the column. The lid was closed and 
centrifuged at 13000rpm for 15s. flow through was discarded. 
6. 500 µl RPE buffer was added to the column and centrifuged for 2min at 
13000rpm, again it was centrifuged. 
7. Then the column was transferred to a new 1.5ml collection tube. To this 30-50 
µl RNase free water was added to the spin column membrane. Closed the lid 
and centrifuged for 1 min at 13000rpm for elution the RNA. 
8. If the expected RNA yield is >30µg repeated last step using another 30-50µl of 
RNase free water or using the elute from last step. The spin column was reuse 
for last step. 
9. Then the eluted RNA placed in ice. 
 
MICRORNA ISOLATION: 
The miRNA isolation was done by using the mirVana™ miRNA Isolation Kit 
1. After trypsinization, cells were collected and washed with PBS. Cells pellet 
were taken and kept in ice. 
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2. For removal of PBS 600µl lysis/binding solution was added. 
[*if cells are 100s in number-300µl] 
[*if cells are 1000s in number-600µl] 
3. The solution was Vortexed vigorously for homogenous lysate. 
4. The 1/10th volume (60 µl) of miRNA homogenate additive added to the cell and 
mixed well by vortexing for several times. The cells placed on ice for 10min. 
5. 1 volume (600µl) of acid phenol chloroform was added which equal of the lysate 
volume and vortexed for 30-60sec for mixing. 
6. Centrifugation was done for 5min at 10,000g at RT for separation the aqueous and 
organic phases. 
7. The aqueous phase was removed carefully without disturbing the lower phase and 
transfers it to the fresh tube. 
        [*the volume removed was noted.] 
8. 1.25 volume of removed aqueous phase was measured and 100% ethanol of same 
volume was added to it.  
9. Then the filter cartridge was placed into one of the collection tubes. The ethanol 
was mixed properly with pipette and transferred onto the filter cartridge. The cells 
were centrifuged for 15s sec at 10000rpm. Flow through was discarded and repeated 
until the lysate/ethanol was through then the collection tube was reused for wash. 
10. 700µl miRNA wash solution 1 was added to the filter catridge and centrifuge for 
5-10sec. The flow through was discarded. 
11. 2/3 of wash solution (500µl) was added and centrifuged for 5-10sec. This step was 
repeated again. 
12. After discarding the flow through from last wash and filtered catridge in the same 
collection tube. The pallet was spin assembly for 1min for removal of residual fluid 
from filter. 
13. Filter catridge was transferred into a fresh collection tube. The 100 µl of preheated 
elution solution added to the centre of the filter and closed the cap. Spin was done for 
20-30 sec at maximum spead to recovery the RNA. 
14. The eluent was collected and stored at -200 c. 
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NANODROP READING 
 RNA was quantified by using the nanodrop spectrophotometer. The OD was 
measured at 260nm wave length. The highest peak was at 260nm. The purity of DNA was 
determined by calculating the OD at 260/280 value. DNA concentration was determined 
based on the following formula. 
1 OD260=40µg ssRNA/ml 
cDNA SYNTHESIS OF mRNA 
The steps in cDNA synthesis: 
1. For each reaction, the following components mixed in a sterile 0.2 or 0.5ml tube. 
 
 
 
2. Each of the components were mixed and briefly centrifuged before use. 
3. The RNA/primer mixture was incubated at 65·c for 5 minutes, and then placed on 
ice for at least 1 minute. 
 
4. In a separation tube, the following 2X reaction was prepared by adding each 
component in the indicated order. 
Components Amounts 
10x RT buffer 2μl 
25mM Mgcl2 4 μl 
0.1 M DTT 2 μl 
RNase OUT   1μl 
Components Amounts 
RNA 
 
4 μl 
10 mM dNTP mix 
 
1μl 
 
Primer (0.5μg/μl oligo (dT)12-18 or 2μM gene 
specific primer) 
 
1 μl 
DEPC treated water 4 μl 
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5. 9μl of the 2X reaction mixture was added to each RNA/primer mixture from step3, 
mixed gently and collected by briefly centrifuge. 
6. It was incubated at 42°c for 2 minutes. 
7. 1μl of super script TM II RT was added to each tube. 
8. It was incubated at 42°c for 50 minutes. 
9. The reaction was terminated at 70·c for 15 minutes and then chilled on ice. 
10. The reaction was collected by brief centrifugation. 1μl of RNase H was added to each 
tube and incubated for 20minutes at 37·c. The reaction was used for PCR 
immediately. 
 
 
cDNA SYNTHESIS OF miRNA: 
 
The cDNA was prepared from the miRNA by using the Invitrogen’s NCode™ VILO™ 
miRNA cDNA Synthesis Kit 
 
1. For the cDNA synthesis of the miRNA the undiluted cDNA are used. 
2. For a single reaction the following component were taken in a tube on ice. 
 
 
 
 
step-1            step-2                                                       step3 
650 C 
5min 
420 C 
2min 
420 C 
50min
700C 
15min 
40 C α 
370 C 
20min 
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Component Amount 
5x Reaction mix 4µl 
10x superscript enzyme mix 2µl 
Total RNA 1.5µl 
DEPC water 12.5µl 
 
3. Then it was incubated at 370 c for 60min. 
4. The reaction was terminated at 950 c for 5min and kept at hold at 40 c until the use. 
 
Quantitative Real Time PCR (qRT-PCR) Analysis 
                 Real-time PCR is the process where the DNA sequences are amplified 
exponentially and the fluorescent signal emitted during each step is measured over a range of 
cycles. Quantitative RT-PCR converts the fluorescent signals from each reaction into a 
numerical value for each sample. Fluorescent dyes was used which binds to the DNA. 
Therefore, as the number of gene copies increases during the reaction so the fluorescence 
intensity increases. This is advantageous because the rate of the reaction and efficiency can 
be seen. The SYBR green dye fluoresces only when bound to double-stranded DNA. The 
disadvantage of using a SYBR green dye is the lack of specificity. We performed the 
quantitative analysis of two genes CX3CL1 and ADAMTS5 in breast cancer cell line. 
 
Procedure for mRNA 
                To perform qRT-PCR, RNA was used as a starting template which must first be 
reverse transcribed into cDNA in a reverse transcription (RT) reaction. The cDNA is then 
used as template for real-time PCR with gene specific primers.  
 
i) SYBR ® Green master mix:- 
The concentration stock solution was 2X and a working solution of 1 X was prepared. 
ii) cDNA Dilution: 
A 1:10 dilution of cDNA was prepared 
iv) Primer: -  
Final Concentration - 500nM  
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Preparation 
2cDNA X 2Gene X 3(triplicate)=12 X10 µl= 120µl +10 µl(one reaction extra)=130 µ 
Sybergreen(Master Mix)=5 µl X 13= 65 µl 
Forward Primer (F.P) = 0.5 X 13 = 6.5 µl 
Reverse Primer (R.P)=0.5 X 13 =6.5 µl 
cDNA = 3 X 13 =39 µl 
 
   Total   = 117 µl 
 
Master Mix 65 µl +13 µl water =78 µl 
 
 
 
                                   39 µl                       39µl 
 F.P.(reference gene) 3.25 µl                    3.25 µl(test gene) 
 R.P                            3.25 µl                   3.25 µl 
 
                   Toatal =45 µl 
 
 
                  22.75 µl        22.75 µl 
 cDNA         9.75 µl         9.75 µl  
(control sample)               (cDNA test sample) 
 
Total = 32.50 µl (then it is divided into 3 triplicate 10 µl reaction in each pcr tube) 
Precaution: don’t expose the reaction to the light 
                  Pipeting error should be avoid. 
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mRNA PRIMER 
 
 
mRNA PCR Condition 
miRNA PRIMER 
PRIMER LENGTH TYPE SEQUENCE 
hsa-miR-17-5p 23 Forward 5’-CAAAGUGCUUACAGUGCAGGUAG-3’ 
hsa-miR-27-3p 21 Forward 5’-UUCACAGUGGCUAAGUUCCGC-3’ 
PRIMER START TYPE SEQUENCE 
ADAMTS5  23 forward 5’-GAACATCGACCAACTCTACTCCG-3’ 
 
20 reverse 5’-CAATGCCCACCGAACCATCT-3’ 
 
CX3CL1 19 forward 5’-ACCACGGTGTGACGAAATG-3’  
 
23 reverse 5’-TGTTGATAGTGGATGAGCAAAGC-3’ 
 
Beta Actin 21 forward 5’- CATGTACGTTGCTATCCAGGC-3’ 
21 Reverse 5’- CTCCTTAATGTCACGCACGAT-3’ 
37 | P a g e  
 
U6 25 Forward 5’-GTGCTCGCTTCGGCAGCACATATAC-3’ 
U6 27 Reverse 5’-AAAAATATGGAACGCTTCACGAATTTG-3’ 
 
 
 
                                                          miRNA PCR Condition: 
 
DNA ISOLATION 
1. The harvested cells were collected. 106 cells were pelleted down at 13000rpm 
for 6min. 
2. Then it was washed with the PBS. 
3. 60µl RIPA buffer and 5 µl proteinase K was added to it and incubated for the 
5min at 40 C. Then tube was placed 250 C for 10min. 
4. 600 µl phenol was added and kept for 10min. 
5. Then it was taken for the centrifuged at 40 C at 6000rpm for 10min. 
6. Supernatant was taken in a fresh tube. 
7. Then phenol:chloroform + isoamylalcohol taken in 24:1 in 1:1 volume was 
added to the supernatant. 
8. This process was repeated 2 times. 
9. Then it was mixed for 10min and centriguge 6000rpm for 10min at 40 C. 
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10. The supernatant was taken and was added 600 µl chloroform and mixed it for 
5min and centrifuge 6000rpm in 40 C for 10min. 
11. Then 500 µl (same volume) isopropanol (chilled) was added and 1/10 volume 
of 3M sodium acetate was added and mixed properly. 
12. After that it was kept under ice (40 C) for 2hr and then centrifuged at 
13000rpm for 20min. 
13. Then it was washed with 70% of ethanol for 2 times. 
14. It was centrifuged at 13000rpm for 30min to remove excess ethanol. Then it 
was kept for air drying. 
BISULFITE DNA CONVERSION 
                         Bisulfite conversion is a method which provides detailed information on the 
methylation pattern of individual DNA molecules at single CG site. The method is based on 
the deamination of unmethylated cytosine residues to uracil in the presence of NaOH and 
sodium bisulfite where the methylated cytosines remains unchanged. The original 
methylation state of the DNA can be analyzed by sequencing of the converted DNA. After 
the conversion reaction, the DNA sequence under investigation is amplified by polymerase 
chain reaction (PCR) with primers specific for one strand of the bisulfite-converted DNA 
(Zhang et al., 2009). 
PROCEDURE 
1. in Bisulfite reactions the thaw DNA was used. Required number of aliquots of Bisulfite 
Mix was dissolved by adding 800 μl RNase-free water to each aliquot. Bisulfite Mix was 
completely dissolved by vortexing. This was taken up to 5 min. 
Note: If necessary, heat the Bisulfite Mix–RNase-free water solution to 60°C and vortex 
again. 
Note: Do not place dissolved Bisulfite Mix on ice. 
2. Bisulfite reaction was prepared in 200 μl PCR tubes according to Table 1.Each component 
was added orderly. 
Note: The combined volume of DNA solution and RNase-free water must total 20 μl. 
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Bisulfite reaction components 
Component Volume per reaction 
DNA solution Variable (max 20µl) 
RNase free water Variable 
Bisulfite mix 85 
DNA protect Buffer 35 
Total volume 140 
 
3. PCR tubes were closed and bisulfite reactions mixed thoroughly. The tubes were stored at 
room temperature (15–25°C).  
4. Bisulfite DNA conversion was performed using below thermal conditions. 
Step Time Temperature 
Denaturation 5min 95 
Incubation 25min 60 
Denaturation 5min 95 
Incubation 85min 60 
Denaturation 5min 95 
Incubation 175min 60 
Hold Infinite 20 
 
Cleanup of bisulfite converted DNA  
6. When the bisulfite conversion was completed, PCR tubes containing the bisulfite reactions 
were centrifuged, and then transferred the complete bisulfite reactions to clean 1.5 ml 
microcentrifuge tubes.  
7. 560 μl freshly prepared Buffer BL was added which containing 10 μg/ml carrier RNA to 
each sample. The solution was mixed by vortexing and then centrifugation was done briefly. 
8. Necessary number of EpiTect spin columns and collection tubes were placed in a suitable 
rack. Entire mixture was transferred from each tube in step 7 into corresponding EpiTect spin 
column.  
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9. Spin columns was centrifuged at maximum speed for 1 min. The flow-through was 
discarded, and placed the spin columns back into the collection tubes.  
10. 500 μl Buffer BW was added to each spin column, and was centrifuged at maximum 
speed for 1 min. flow-through was discarded, and placed the spin columns back into the 
collection tubes.  
11. 500 μl Buffer BD was added to each spin column, and incubated for 15 min at room 
temperature (15–25°C).spin columns was centrifuged at maximum speed for 1 min. flow-
through was discarded, and spin columns was placed back into the collection tubes.  
13. 500 μl Buffer BW was added to each spin column and centrifuged at maximum speed for 
1 min. flow-through was discarded and spin columns were placed back into the collection 
tubes. 
14. Step 13 was repeated again. 
15. Spin columns were placed into new 2 ml collection tubes, and spin columns were 
centrifuged at maximum speed for 1 min. 
16. Recommended: spin columns were placed with open lids into clean 1.5 ml micro-
centrifuge tubes (not provided) and spin columns was incubated for 5 min at 56°C in a 
heating block. This step was enables evaporation of any remaining liquid.  
17. Spin columns were placed into clean 1.5 ml micro-centrifuge tubes (not provided). 20 μl 
Buffer EB was dispensed onto the center of each membrane.  Purified DNA was eluted by 
centrifugation for 1 min at approximately 15,000 x g (12,000 rpm).  
 
MSP (Methylation specific PCR) 
                Methylation specific PCR is a quantitative technique used for detecting the 
presence of methylation in bisulfite converted DNA. Primers to detect methylated DNA are 
designed under the assumption that the region will be fully methylated and thus will contain 
cytosine in the bisulphite converted sequences at CG dinucleotides. Unmethylated DNA are 
designed assuming the region to be unmethylated and therefore containing thymine rather 
than cytosine at CG dinucleotides. The annealing temperature for methylated primer will be 
higher than that of unmethylated primers. 
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PROCEDURE 
                     For experiment two types of primers are used, one for the methylated DNA and 
the other for unmethylated DNA.  
 
PRIMER TYPE SEQUENCE 
Cx3cl1 (methylated) Forward 5’-GGTGAGAAGTTTAGGGATATAAAGTC-3’ 
Reverse 5’-AAACTCAATACTATCCCCTTACCG-3’ 
Cx3cl1 (un-methylated) Forward 5’-GAGAAGTTTAGGGATATAAAGTTGG-3’ 
Reverse 5’-AAACTCAATACTATCCCCTTACCAC-3’ 
 
 
The following reaction mix was for prepared the pcr reaction. 
Component  Final Concentration 
PCR buffer 1x 
MgCl2 1.5mM 
Template 0.4 
Forward primer 200nM 
Reverse primer 200nM 
dNTP 200nM 
DNA polymerase 1.25 per 50µl 
 
PRIMER TYPE SEQUENCE 
ADAMTS5  
(methylated) 
Forward 5’-TAAAATAAGAAAGGAAGTGGGTTTC-3’ 
Reverse 5’-TCGAATAATAAAAATTCAACAAATACG-3’ 
ADAMTS5  
(un-methylated) 
Forward 5’-TCGAATAATAAAAATTCAACAAATACG-3’ 
Reverse 5’-AAATAATAAAAATTCAACAAATACAAA-3’ 
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The above reaction mix was prepared properly and the template was amplified using Touch-
Down PCR cycle conditions. 
Phase1: 
Step Temperature Time 
Denature 95 3min 
Denature 95 30sec 
Anneal Tm+10 45sec 
Elongate 72 60sec 
 
Phase 2 
Step Temperature Time 
Denature 95 30sec 
Anneal Tm/Tm-5c 45sec 
Elongate 72 60sec 
 
Termination: 
Step Temperature Time 
Elongate 72 5 
Halt reaction 4 15 
Hold 23 INFINITE 
 
 
 
 
 
 
  
 
 
 
 
RESULTS AND DISCUSSIONS 
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RESULTS AND DISCUSSIONS 
Microarray Analysis 
 
                                         Figure 11: Analysis of all entities in the samples 
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HIERARCHIAL CLUSTERING OF THE mRNA and miRNA 
 
 
 
 
                           Figure 12: Hierarchical clustering of mRNAs and miRNAs 
From above microarray data analysis, we found 195 mRNAs to be down-regulated and 42 to 
be up-regulated. Microarray analysis of miRNA datasets yielded 122 miRNAs that are down 
regulated and 75 up regulated. 
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TARGET ANALYSIS INTERACTION MAP: 
The interconnected network of mRNAs-miRNAs-transcription factors was generated as an 
interaction map. 
 
 
Figure13: Interaction Map of differentially expressed mRNAs and miRNAs 
 
From the Interaction map, ADAMTS5 was selected which is targeted by the hsa-miR-27a. 
The ADAMTS5 is expected to be down-regulated in breast cancer and the hsa-miR-27a is 
expected to be up regulated is breast cancer. 
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Interaction study by NCI pathway analysis tool 
 
 
 
                           Figure 14: Interaction Map of CX3CL1 with p53  
 
 
The NCI pathway analysis tool provided an enrichment analysis of the down-regulated genes 
in breast cancer. From this functional categorisation of the genes, CX3CL1 (fractalkine) a 
key gene involved in p53 mediated DNA damage response was chosen for further analysis.  
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EXPERIMENTAL VALIDATIONS 
 
RNA ISOLATION 
Cells were collected from test cell line (MDA-MB 231) as well as control cell line (HaCaT). 
RNAs was isolated by using the desired kit and was quantified using nanodrop 
spectrophotometer. The OD was measured at 260 nm wavelength and 280 nm wave length. The 
highest peak was at 260 nm. The purity of RNA was determined by calculating the OD at 
260/280 value. The RNA concentration was determined based on the following formula 
1 OD260 =40µg ssRNA/ml 
 
Quantification of mRNA 
RNAs AMOUNT 260/280nm 
Control 931.1 µg/ml 2.47 
Infected 889.3 µg/ml 1.93 
 
Quantification of miRNA: 
RNAs AMOUNT 260/280nm 
Control 1611.5 µg/ml 2.04 
Infected 1127.4 µg/ml 1.89 
 
REAL TIME PCR 
                 The qRT-PCR was performed for the quantitative analysis of the both the mRNAs 
as well as miRNA. The two gene CX3CL1 and ADAMTS5 were considered along with 
reference gene, beta Actin and their expression was quantified in both test and control 
samples. 
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ADAMTS5 
 
Figure15: Melting Curve of ADAMTS5 with respect to the control gene 
 
miRNA qRT-PCR: 
            The two miRNA hsa-miR-27a-3p and hsa-miR-17-5p were taken with the control U6.  
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hsa-miR-27a-3p: 
 
                      Figure16: Melting Curve of the hsa-miR-27a-3p with respected the U6 
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MELTING CURVE OF hsa-miR-17-5p and hsa-miR-27a-3p 
 
 
Figure17: Melting curve of hsa-miR-17-5p and hsa-miR-27a-3p 
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BAR DIAGRAM OF miRNA AND mRNA EXPRESSION: 
 
                                                                 (a) 
 
                                                                 ( b)   
           Figure 18: Fold change of miR-27a-3p, miR-17-5p, ADAMTS5 and CX3CL1 in 
breast cancer (MDA-MB-231 cell lines) obtained from qRT-PCR  
(a) Above bar graph represents miRNAs to be highly expressed in the test sample in 
comparison to normal sample. (b) Simultaneously the mRNA levels is found to be down 
regulated in the test sample with respect to their fold change (FC=2-
 Δ ΔCT
). 
  
 
 
 
 
CONCLUSIONS 
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CONCLUSIONS 
In our study, we mainly focused on the differentially expressed mRNAs and miRNAs which 
regulate the breast cancer. The targets are identified and studied to analyse the mechanism of 
miRNA targeting in breast cancer.  
We analysed expression data of human breast cancer tissues obtained from Gene 
Omnibus database (GSE ID: 10797) to find out significantly expressed genes. 33 samples 
were used in this analysis, out of which 5 samples were from breast epithelial tissues (used as 
control) and 28 samples were from cancer epithelial tissues (used as test). We obtained a set 
of differentially expressed mRNAs that comprised of 195 down regulated genes and 42 up 
regulated genes. We also analysed the miRNA expression of breast cancer (GSE ID: 38867) 
and obtained 122 down regulated and 75 up regulated miRNAs.  
By using the different web based tools, interaction studies were done. From that 
interaction map, we found that ADAMTS5 is targeted by hsa-miR-27a-3p. From the NCI 
pathway analysis, we found that CX3CL1 have more potential role by targeting p53 in breast 
cancer which has target site for hsa-miR-17-5p. 
Experimental validation by was done for both of the above mentioned mRNAs and 
miRNA using quantitative RT-PCR and found that ADAMTS5 is down regulated and hsa-
miR-27a-3p is up regulated in breast cancer. The down-regulation of this gene leaves scope 
for a hypothesis that it may be due to being targeted by has-miR-27a-3p which is highly 
expressed in breast cancer. From the qRT-PCR, we also found that CX3Cl1 is down-
regulated and hsa-miR-17-5p is highly regulated. 
For better understanding of the mode of regulation of such genes, we attempted 
Methylation analysis of respective promoter sequences through MSP, but were not 
successful.  Further study is needed for the MSP validation.  
 
 
 
 
 
  
 
 
 
 
FUTURE PROSPECTIVES 
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FUTURE PROSPECTIVES 
Curable rate of breast cancer patient is less compared to increased incidence of breast cancer. 
Identifying the molecular mechanisms responsible for breast cancer malignancy will be 
helpful for improving therapeutic uses. The further study and validation of ADAMTS5 and 
CX3CL1 which are predicted to be targeted by hsa-miR-27a-3p and hsa-miR-17-5p 
respectively by luciferase assay will shed light on mode of regulation of these genes. Further 
functional experimental validations will disclose the significance of these de-regulations in 
breast cancer to understand the mechanisms underlying this malignancy which ultimately 
may help to discover new ways of incorporating miRNA in cancer therapeutics. 
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